Prospective Trial for the Evaluation of Radiogenomics in Advanced Rectal Cancer

National Cancer Center, Korea210 enrolled

Overview

In patients with advanced rectal cancer, molecular subtypes will be identified by preoperative biopsy, CT, MRI / PET radiomics analysis, clinical features, and clinical features will be confirmed and compared. Also, we want to confirm the relationship between these factors and the treatment response after chemoradiotherapy before surgery. The prognosis will be then assessed through 5-year overall survival and 3-year disease free survival. A prospective clinical trial, recruiting 210 persons (approximately 53 per year) that meet the selection criteria for approximately four years from the IRB approval date in 2019 (about 53 per year) We will analyze the data and then collect and analyze the data and report the results.

Study Type

OBSERVATIONAL

Enrollment

210

Conditions

Rectal Cancer

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age: 20-80 years * Patients diagnosed with mid-lower rectal cancer and expected to receive chemoradiotherapy before surgery Exclusion Criteria: * Patients with distal metastases confirmed at diagnosis * Patients with other bowel diseases such as IBD, ischemic colitis and TB colitis in addition to colorectal cancer * If patients do not agree with this study

Locations (1)

National Cancer Center

Goyang-si, Gyeonggi-do, South Korea

Outcomes

Primary Outcomes

K-RAS Mutation

K-RAS Mutation status

Time frame: 4 weeks

Secondary Outcomes

Radiomics - MR image findings

Radiologic features